114 related articles for article (PubMed ID: 25340610)
1. Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation.
Dietrich S; Radujkovic A; Stölzel F; Falk CS; Benner A; Schaich M; Bornhäuser M; Ehninger G; Krämer A; Hegenbart U; Ho AD; Dreger P; Luft T
Transplantation; 2015 May; 99(5):1065-71. PubMed ID: 25340610
[TBL] [Abstract][Full Text] [Related]
2. Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation.
Schwarzbich MA; Dai H; Kordelas L; Beelen DW; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216457
[TBL] [Abstract][Full Text] [Related]
3. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
4. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.
Juliusson G; Karlsson K; Lazarevic VLj; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M;
Cancer; 2011 Sep; 117(18):4238-46. PubMed ID: 21387283
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.
Meijer E; Cornelissen JJ
Semin Oncol; 2008 Aug; 35(4):449-57. PubMed ID: 18692695
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
Novitzky N; Thomas V; du Toit C; McDonald A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
Lodewyck T; Cornelissen JJ
Blood Rev; 2008 Nov; 22(6):293-302. PubMed ID: 18455284
[TBL] [Abstract][Full Text] [Related]
11. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.
Hemmati PG; Terwey TH; le Coutre P; Vuong LG; Massenkeil G; Dörken B; Arnold R
Eur J Haematol; 2011 Apr; 86(4):305-16. PubMed ID: 21265883
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis.
Stelljes M; Krug U; Beelen DW; Braess J; Sauerland MC; Heinecke A; Ligges S; Sauer T; Tschanter P; Thoennissen GB; Berning B; Kolb HJ; Reichle A; Holler E; Schwerdtfeger R; Arnold R; Scheid C; Müller-Tidow C; Woermann BJ; Hiddemann W; Berdel WE; Büchner T
J Clin Oncol; 2014 Feb; 32(4):288-96. PubMed ID: 24366930
[TBL] [Abstract][Full Text] [Related]
13. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
[TBL] [Abstract][Full Text] [Related]
14. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia.
Cornelissen JJ; Löwenberg B
Hematology Am Soc Hematol Educ Program; 2005; ():151-5. PubMed ID: 16304373
[TBL] [Abstract][Full Text] [Related]
15. Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.
Aoki J; Ishiyama K; Taniguchi S; Fukuda T; Ohashi K; Ogawa H; Kanamori H; Eto T; Iwato K; Sakamaki H; Morishima Y; Nagamura T; Atsuta Y; Takami A
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2029-33. PubMed ID: 25196856
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies.
Radujkovic A; Kordelas L; Krzykalla J; Beelen DW; Benner A; Lehners N; Schmidt K; Dreger P; Luft T
J Clin Oncol; 2017 Sep; 35(27):3143-3152. PubMed ID: 28771378
[TBL] [Abstract][Full Text] [Related]
17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
18. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
20. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
